MedTrace Logo

Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements

NCT02525107 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2015-08-17

No results posted yet for this study

Summary

140 SCD patients \[70 on Hydroxyurea\] will receive Omega-3 capsules whereas another 140 SCD patients \[70 on Hydroxyurea\] will receive placebo and will be recruited from the Sultan Qaboos University Hospital \[SQUH\] haematology specialty clinics. Patients will be randomized in a 1:1 ratio to receive placebo or Omega-3 for 52 weeks. The aim is to investigate the therapeutic potential of omega-3 fatty acids in the prevention of vaso-occlusive crisis in Omani patients with sickle cell disease\[SCD\].

Conditions

Interventions

DIETARY_SUPPLEMENT

Omega-3 capsules

SCD patients on Hydroxyurea

DIETARY_SUPPLEMENT

Placebo

SCD patients on Hydroxyurea

DIETARY_SUPPLEMENT

Omega-3 capsules

SCD patients not on Hydroxyurea

DIETARY_SUPPLEMENT

Placebo

SCD patients not on Hydroxyurea

Sponsors & Collaborators

  • Ministry of Health, Sultanate of Oman

    collaborator UNKNOWN

  • London Metropolitian University

    collaborator UNKNOWN

  • Sultan Qaboos University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2019-01-31
Completion
2019-03-31

Countries

  • Oman

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02525107 on ClinicalTrials.gov